Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q2 2021 · 10-Q
Revenue$9.06M$9.06Mno prior Q2 2020 on file Net Income$1.23M$1.23Mno prior Q2 2020 on file EPS Diluted$0.08$0.08no prior Q2 2020 on file Operating Income-$1,435,729— Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$2,684,148— Margins · derivedOperating margin-15.9%
Net margin13.6%
ended Jun 30, 2021 · filed Aug 13, 2021 · 44 d after period end